This inventor holds 31 USPTO granted patents and 1 published patent application and 7 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, The Dupont Merck Pharmaceutical Company, Syngene International Limited. Active years: 1994-2025.
Location History:
- Swarthmore, DE (US) (1994)
- Swarthmore, PA (US) (1995 - 2024)
Company Filing History:
20 out of 3,735 
5 out of 206 
4 out of 7 
Years Active: 1994-2025
Areas of Expertise:
Title: Steven P Seitz: Innovator in Medical Patents
Introduction: Steven P Seitz is a renowned inventor based in Swarthmore, PA, whose contributions to the field of pharmaceuticals are significant. With a remarkable portfolio of 28 patents, he has a proven track record of creating innovative solutions for treating various medical conditions, particularly proliferative disorders.
Latest Patents: Among his latest inventions are two notable patents: the first focuses on NLRP3 modulators, providing compounds that serve as potential medicaments for the treatment of proliferative disorders, including cancer. The second invention involves uracil derivatives as Mer-Axl inhibitors, which may be utilized in pharmaceutical compositions and methods to address cancers and disorders characterized by dysregulated apoptosis.
Career Highlights: Steven's career has seen impactful roles at prestigious companies, including Bristol-Myers Squibb Company and the DuPont Merck Pharmaceutical Company. His work at these institutions has facilitated the development of groundbreaking treatments and reinforced his status as a key figure in pharmaceutical innovation.
Collaborations: Throughout his career, Steven has collaborated with esteemed colleagues such as Jay A Markwalder and James Aaron Balog. These collaborations have fostered an environment of creativity and invention, allowing for the exploration of new therapeutic avenues in medicine.
Conclusion: Steven P Seitz is an inventive force in the pharmaceutical industry, with a strong emphasis on developing effective treatments for serious health conditions. His extensive patent portfolio and collaborative efforts demonstrate his commitment to innovation and improving patient outcomes.